Comparative in vitro activity of Delafloxacin and other antimicrobials against isolates from patients with acute bacterial skin, skin-structure infection and osteomyelitis.

Autor:	Ribeiro ÁCDS; Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicinan (EPM), Departamento de Medicina Interna, Divisão de Doenças Infecciosas, Laboratório Alerta, São Paulo, SP, Brazil. Electronic address: aghata.cardoso@unifesp.br., Santos FF; Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicinan (EPM), Departamento de Medicina Interna, Divisão de Doenças Infecciosas, Laboratório Alerta, São Paulo, SP, Brazil., Valiatti TB; Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicinan (EPM), Departamento de Medicina Interna, Divisão de Doenças Infecciosas, Laboratório Alerta, São Paulo, SP, Brazil., Lenzi MH; Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicinan (EPM), Departamento de Medicina Interna, Divisão de Doenças Infecciosas, Laboratório Alerta, São Paulo, SP, Brazil., Santos INM; Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicinan (EPM), Departamento de Medicina Interna, Divisão de Doenças Infecciosas, Laboratório Alerta, São Paulo, SP, Brazil., Neves RFB; Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicinan (EPM), Departamento de Medicina Interna, Divisão de Doenças Infecciosas, Laboratório Alerta, São Paulo, SP, Brazil., Moses IB; Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicinan (EPM), Departamento de Medicina Interna, Divisão de Doenças Infecciosas, Laboratório Alerta, São Paulo, SP, Brazil; Ebonyi State University, Faculty of Science, Department of Applied Microbiology, Abakaliki, Nigeria., Meneses JP; Eurofarma, Brazil., Di Sessa RGG; Eurofarma, Brazil., Salles MJ; Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicinan (EPM), Departamento de Medicina Interna, Divisão de Doenças Infecciosas, Laboratório Alerta, São Paulo, SP, Brazil., Gales AC; Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicinan (EPM), Departamento de Medicina Interna, Divisão de Doenças Infecciosas, Laboratório Alerta, São Paulo, SP, Brazil.
Jazyk:	angličtina
Zdroj:	The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases [Braz J Infect Dis] 2024 Sep 18; Vol. 28 (6), pp. 103867. Date of Electronic Publication: 2024 Sep 18.
DOI:	10.1016/j.bjid.2024.103867
Abstrakt:	The aim of this study was to compare the in vitro activity of delafloxacin with other fluoroquinolones against bacterial pathogens recovered from inpatients with osteomyelitis, Acute Bacterial Skin and Skin-Structure Infections (ABSSSI). In total, 100 bacterial isolates (58 % Gram-negative and 42 % Gram-positive) recovered from inpatients between January and April 2021, were reidentified at species level by MALDI-TOF MS. Antimicrobial susceptibility testing was conducted using the broth microdilution method and the detection of biofilm formation was assessed through the microtiter plate assay. The screening for mecA was carried out by PCR, while mutations in the Quinolone Resistance Determining Regions (QRDR), specifically gyrA and parC, were analyzed using PCR followed by Sanger sequencing. Results showed that delafloxacin exhibited greater in vitro potency (at least 64-times) than the other tested fluoroquinolones (levofloxacin and ciprofloxacin) when evaluating Staphylococcus aureus (MIC 50 ≤0.008 mg/L) and coagulase-negative Staphylococcus (MIC 50 0.06 mg/L). Furthermore, delafloxacin (MIC 50 0.25 mg/L) was at least 4 times more potent than other tested fluoroquinolones (MIC 50 1 mg/L) against P. aeruginosa. No difference in delafloxacin activity (MIC 50 0.03 mg/L) was observed against Enterobacter cloacae when compared with ciprofloxacin (MIC 50 0.03 mg/L). Despite presenting low activity against K. pneumoniae isolates (22.2 %), delafloxacin exhibited twice the activity compared to both levofloxacin and ciprofloxacin. Delafloxacin also exhibited a strong activity (71.4 %‒85.7 %.) against biofilm producing bacterial pathogens tested in this study. Interestingly, 82.14 % of the staphylococci tested in this study harbored mecA gene. In addition, the gyrA and parC genes in fluoroquinolone-resistant Gram-negative isolates displayed different mutations (substitutions and deletions). Herein, we showed that delafloxacin was the most active fluoroquinolone against staphylococci (including MRSA) and P. aeruginosa when compared to other fluoroquinolones such as ciprofloxacin and levofloxacin. Competing Interests: Conflicts of interest The authors declare no conflicts of interest. (Copyright © 2024 Sociedade Brasileira de Infectologia. Published by Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu